Zurcher Kantonalbank Zurich Cantonalbank lowered its stake in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 15.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,991 shares of the biotechnology company’s stock after selling 756 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Heron Therapeutics were worth $98,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Norges Bank purchased a new stake in Heron Therapeutics in the fourth quarter worth about $13,679,000. Boston Advisors LLC grew its holdings in Heron Therapeutics by 443.9% in the first quarter. Boston Advisors LLC now owns 134,559 shares of the biotechnology company’s stock worth $3,288,000 after purchasing an additional 109,819 shares during the period. Los Angeles Capital Management & Equity Research Inc. grew its holdings in Heron Therapeutics by 144.6% in the fourth quarter. Los Angeles Capital Management & Equity Research Inc. now owns 19,690 shares of the biotechnology company’s stock worth $511,000 after purchasing an additional 11,640 shares during the period. Legal & General Group Plc grew its holdings in Heron Therapeutics by 6.5% in the fourth quarter. Legal & General Group Plc now owns 27,564 shares of the biotechnology company’s stock worth $716,000 after purchasing an additional 1,679 shares during the period. Finally, Congress Park Capital LLC grew its holdings in Heron Therapeutics by 32.2% in the fourth quarter. Congress Park Capital LLC now owns 46,575 shares of the biotechnology company’s stock worth $1,208,000 after purchasing an additional 11,350 shares during the period.
A number of equities research analysts have recently commented on HRTX shares. ValuEngine upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 4th. BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, February 5th. Stifel Nicolaus reiterated a “buy” rating and set a $54.00 price target on shares of Heron Therapeutics in a report on Friday, February 22nd. Cantor Fitzgerald set a $50.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Friday, February 22nd. Finally, Northland Securities reiterated a “buy” rating on shares of Heron Therapeutics in a report on Monday, March 11th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $51.20.
In related news, Director Waage Christian acquired 1,400 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average price of $18.04 per share, for a total transaction of $25,256.00. Following the completion of the transaction, the director now directly owns 1,400 shares in the company, valued at $25,256. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John Poyhonen acquired 3,000 shares of the stock in a transaction that occurred on Wednesday, May 22nd. The shares were bought at an average price of $17.55 per share, for a total transaction of $52,650.00. Following the transaction, the director now owns 13,000 shares of the company’s stock, valued at $228,150. The disclosure for this purchase can be found here. 12.56% of the stock is owned by corporate insiders.
Shares of NASDAQ:HRTX traded up $0.45 during trading on Friday, reaching $18.18. 668,454 shares of the stock traded hands, compared to its average volume of 1,098,530. Heron Therapeutics Inc has a 52-week low of $16.20 and a 52-week high of $42.90. The company has a quick ratio of 4.06, a current ratio of 4.40 and a debt-to-equity ratio of 0.04. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of -7.45 and a beta of 1.45.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.50) by ($0.30). The firm had revenue of $31.60 million for the quarter, compared to analysts’ expectations of $28.04 million. Heron Therapeutics had a negative net margin of 194.43% and a negative return on equity of 49.22%. The company’s quarterly revenue was up 172.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.09) EPS. As a group, sell-side analysts anticipate that Heron Therapeutics Inc will post -2.6 earnings per share for the current year.
About Heron Therapeutics
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Recommended Story: Mutual Funds
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.